Related Experiment Videos
Management of viral retinitis
1Department of Ophthalmology, Louisiana State University Medical Center, Shreveport.
Ophthalmic Surgery
|December 1, 1988
Summary
Cytomegalovirus retinitis in AIDS patients is challenging to treat. While ganciclovir shows promise, its virostatic nature necessitates exploring new therapeutic options for viral retinitis.
Area of Science:
- Ophthalmology
- Virology
- Infectious Diseases
Background:
- Viral retinitis is a significant cause of vision loss, primarily attributed to cytomegalovirus (CMV), herpes simplex virus (HSV), and herpes zoster virus (HZV).
- While effective treatments exist for HSV and HZV retinitis, including acute retinal necrosis, CMV retinitis in immunocompromised individuals, particularly those with acquired immune deficiency syndrome (AIDS), remains a therapeutic challenge.
Purpose of the Study:
- To evaluate the efficacy of ganciclovir in treating cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
- To highlight the limitations of current antiviral therapies and the need for alternative treatment strategies for CMV retinitis.
Main Methods:
- Review of existing literature on viral retinitis treatments.
- Analysis of the clinical outcomes of ganciclovir therapy in patients with CMV retinitis and AIDS.
Main Results:
- Ganciclovir has demonstrated a significant reduction in visual morbidity associated with CMV retinitis in AIDS patients.
- However, ganciclovir is virostatic, meaning it inhibits viral replication but does not eliminate the virus, leading to frequent recurrences during and after treatment.
Conclusions:
- Current chemotherapy, including ganciclovir, is insufficient for complete control of CMV retinitis due to its virostatic action and the potential for viral replication.
- There is a critical need to investigate novel therapeutic modalities to effectively manage and potentially cure cytomegalovirus retinitis in immunocompromised patients.